A Phase 1 interventional study of GSK3036656 and Placebo in Tuberculosis, sponsored by GlaxoSmithKline. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-19.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Tuberculosis by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Tuberculosis · GlaxoSmithKline.
Among the 21 studies in Tuberculosis by GlaxoSmithKline, this one is the 16th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 1, and was the 15th registered.
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
Browse Tuberculosis studies →1 of the 21 studies in Tuberculosis by GlaxoSmithKline is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Spain
Ages 18–64 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 150 across 820 interventional studies indexed under Tuberculosis.
Median enrollment 50 across the 21 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Tuberculosis by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07784894GlaxoSmithKlineA Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential | 2026-11-17 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Tuberculosis by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GSK3036656 is being developed by GSK for the treatment of tuberculosis (TB). This is the FTIH study for GSK3036656 to evaluate the safety, tolerability and PK of single ascending and repeat oral doses of GSK3036656 in healthy adult subjects. The results of this study are intended to be used to identify appropriate and well-tolerated doses of GSK3036656 to be used in further studies. A food effect assessment will also be undertaken to investigate the influence of food on the PK of GSK3036656. The study will be conducted in two parts: Part A (single dose) and Part B (repeat dose). Up to two cohorts will be included in Part A. 9 healthy adult subjects will be included in each cohort. Each cohort will participate in up to 4 treatment (dosing) periods including a food effect treatment period. During each treatment period, GSK3036656 will be administered to 6 subjects and placebo will be administered to 3 subjects. The starting dose in Part A will be 5 milligrams (mg), and the maximum dose will be 1500 mg. The two cohorts in Part A will be dosed sequentially (i.e., dosing in Cohort 2 starts after dosing in Cohort 1 is completed). Initially, there will be a 14 day wash out period for individual subjects between each dose level. Study progression to Part B from Part A will be based on an acceptable safety, tolerability and PK profile in Part A. Part B will comprise up to 4 cohorts (Cohorts 3, 4, 5, and 6) each containing 10 (8 active: 2 placebo) healthy adult subjects to examine the safety, tolerability and PK of a repeated daily dose of GSK3036656 over a period of up to 14 days. Appropriate doses and dose regimens for Part B will be selected based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B. Dividing the total daily dose into 2 or 3 smaller doses may be done in both Part A and Part B. Up to 18 subjects will be enrolled into Part A and up to 40 subjects will be enrolled into Part B. The total duration of the study for each subject recruited into Part A and Part B will be approximately 12 weeks and 8 weeks, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non-child bearing potential are eligible to participate. Non-child bearing potential is defined as:
Male subjects with female partners of child bearing potential must comply with the following requirements from the time of first dose of study medication until 90 days after the last dose of study treatment (i.e. one sperm cycle).
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
Drug: GSK3036656
During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
Drug: Placebo
During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
Drug: GSK3036656
During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
Drug: Placebo
During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.
Drug: GSK3036656
During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
Drug: Placebo
During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
Drug: GSK3036656
During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
Drug: Placebo
During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
Drug: GSK3036656
During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
Drug: Placebo
During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
Drug: GSK3036656
During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
Drug: Placebo
GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part A
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above. Safety Population comprised of all randomized participants who received at least one dose of study medication.
Time frame: Up to 12 weeks
Number of Participants With nSAE and SAEs for Part B
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above.
Time frame: Up to 8 weeks
Number of Participants With Abnormal Electrocardiogram (ECG) Findings for Part A
12-lead ECGs were collected during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) intervals. At each time point at which triplicate ECGs were required, three individual ECG tracings were obtained as closely as possible in succession, but no more than 2 to 5 minutes apart. ECG findings were categorized as normal, abnormal not clinically significant (A-NCS) and abnormal clinically significant (A-CS). Only A-NCS and A-CS worst case post-Baseline values have been presented. Only those participants with data available at the indicated time point were analyzed.
Time frame: Up to 6 weeks
Number of Subjects With Clinically Relevant Changes in ECG in Part B
12-lead ECGs were collected during the study using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT interval and QTcF intervals. At each time point at which triplicate ECGs were required, three individual ECG tracings were obtained as closely as possible in succession, but no more than 2 to 5 minutes apart. ECG findings were categorized as normal, A-NCS and A-CS. Only A-NCS and A-CS worst case post-Baseline values have been presented.
Time frame: Up to 8 weeks
Number of Participants With Abnormal Cardiac Telemetry Findings for Part A
Continuous cardiac telemetry was performed from approximately 1 hour pre-dose to 24 hours post dosing . Number of participants who had abnormal findings upon cardiac telemetry assessment have been presented.
Time frame: 25 hours for each period
Number of Participants With Abnormal Cardiac Telemetry Findings for Part B
Continuous cardiac telemetry was performed from approximately 1 hour pre-dose to 24 hours post dosing . Number of participants who had abnormal findings upon cardiac telemetry assessment have been presented.
Time frame: 25 hours for each period
Number of Participants With Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance (PCI) for Part A
SBP and DBP were assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for SBP was less than 85 mmHg (lower) and greater than 160 mmHg (upper) while that for DBP was less than 45 mmHg (lower) and greater than 100 mmHg (upper).
Time frame: Up to 6 weeks
Number of Participants With Vital Sign Parameters SBP and DBP of PCI for Part B
SBP and DBP were assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for SBP was less than 85 mmHg (lower) and greater than 160 mmHg (upper) while that for DBP was less than 45 mmHg (lower) and greater than 100 mmHg (upper).
Time frame: Up to 8 weeks
Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part A
Heart rate was assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for heart was less than 40 bpm (lower) and greater than 110 bpm (upper).
Time frame: Up to 6 weeks
Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part B
Heart rate was assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for heart was less than 40 bpm (lower) and greater than 110 bpm (upper).
Time frame: Up to 8 weeks
Number of Participants With Vital Sign Parameter Temperature of PCI for Part A
Number of participants with temperature data of PCI have been presented.
Time frame: Up to 6 weeks
Number of Participants With Vital Sign Parameter Temperature of PCI for Part B
Number of participants with temperature data of PCI have been presented.
Time frame: Up to 8 weeks
Number of Participants With Clinical Chemistry Parameters of PCI for Part A
Blood samples were collected for the assessment of clinical chemistry parameters namely blood urea nitrogen (BUN), creatinine, glucose, cholesterol, potassium, sodium, calcium, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, triglycerides, total and direct bilirubin, total protein, albumin and troponin. Only categories with PCI values have been presented, therefore only AST is presented.
Time frame: Up to 12 weeks
Number of Participants With Clinical Chemistry Parameters of PCI for Part B
Blood samples were collected for the assessment of clinical chemistry parameters namely BUN, creatinine, glucose, cholesterol, potassium, sodium, calcium, AST, ALT, alkaline phosphatase, triglycerides, total and direct bilirubin, total protein, albumin and troponin. Only categories with PCI values have been presented.
Time frame: Up to 8 weeks
Number of Participants With Hematology Parameters of PCI for Part A
Blood samples were collected for the assessment of hematology parameters platelet count, red blood cell count, hemoglobin, hematocrit, reticulocytes, mean corpuscle volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, basophils and eosinophils. Only categories with PCI values have been presented.
Time frame: Up to 12 weeks
Number of Participants With Hematology Parameters of PCI for Part B
Blood samples were collected for the assessment of hematology parameters platelet count, red blood cell count, hemoglobin, hematocrit, reticulocytes, mean corpuscle volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, basophils and eosinophils. Only categories with PCI values have been presented.
Time frame: Up to 8 weeks
Number of Participants With Abnormal Urinalysis Parameters for Part A
Urinalysis included dipstick urine test which was used to screen for glucose, ketones, occult blood and protein up to 72 hours post dose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, ketones, occult blood and protein can be read as negative, trace, trace-intact, trace-lysed,1+ and 2+ indicating proportional concentrations in the urine sample. Only categories with non-negative values have been presented. Only those participants with data available the indicated time points were analyzed.
Time frame: Up to 72 hours post-dose
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part A
Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 72 hours in Part A. Only those participants with data available at the indicated time points were analyzed.
Time frame: Up to 72 hours post-dose
Number of Participants With Abnormal Urinalysis Parameters for Part B
Urinalysis included dipstick urine test which was used to screen for glucose, ketones, occult blood and protein up to 14 days post dose The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, ketones, occult blood and protein can be read as negative, trace, trace-intact, trace-lysed, 1+ and 2+ indicating proportional concentrations in the urine sample. Only categories with non-negative values have been presented. Only those participants available at the specified time points were analyzed represented by n=x in the category titles. Period 1 = Cohort 1 in Part B, Period 2 = Cohort 2 in Part B.
Time frame: Up to 8 weeks
Urine pH Analysis by Dipstick Method for Part B
Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 8 weeks in Part B. Only those participants available at the specified time points were analyzed represented by n=x in the category titles. Period 1 = Cohort 1 in Part B, Period 2 = Cohort 2 in Part B.
Time frame: Up to 8 weeks
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 Ethylenediaminetetraacetic acid (EDTA) tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. PK population comprised of participants in the Safety population who administered at least one dose of active treatment and had at least one evaluable PK sample.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
AUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part A
Cmax will be derived from the PK samples collected at the indicated time points Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Maximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Apparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
AUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part B
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1. The actual date and time of each blood sample collection was recorded. Results presented are for Day 1.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1
AUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part B
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14The actual date and time of each blood sample collection was recorded. Results presented are for Day 14.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
Cmax of GSK3036656 Following Repeated Dose Administration for Part B
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. The actual date and time of each blood sample collection was recorded.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
Tmax of GSK3036656 Following Repeat Dose Administration for Part B
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. The actual date and time of each blood sample collection was recorded.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
t1/2 of GSK3036656 Following Repeated Dose Administration for Part B
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14. The actual date and time of each blood sample collection was recorded. Results presented are for Day 14.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14.
AUC (0-t) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
AUC (0-infinity) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Cmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
t1/2 of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Tmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Observed Accumulation Ratio Based on AUC (AUC [Ro]) of GSK3036656 in Part B
AUC Ro was calculated as Day 14 AUC(0-tau)/Day 1 AUC(0-t), where t and tau= 24 hours.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
Observed Accumulation Ratio Based on Cmax (RCmax) of GSK3036656 in Part B
Rcmax was calculated as Day 14 Cmax/Day 1 Cmax. Statistics has been presented on geometric least square means.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
Steady State Ratio (Rss) of GSK3036656 in Part B
Rss was calculated as Day 14 AUC (0-tau)/Day 1 AUC (0-inf). It was not possible to calculate AUC(0-inf) on Day 1 for the repeat dosing period, therefore it was not possible to calculate the (Rss).Na indicates data was not available.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
Trough Plasma Concentrations at the End of the Dosing Interval (Ctau) of GSK3036656 Following Repeat Dose Administrations in Part B
Blood samples for the analysis of Ctau were collected at Day 1 (24 hours), Day 12 (Pre-dose ), Day 13 (Pre-dose ), Day 14 (Pre-dose), Day 14 (24 hours). Ctau samples collected were used to assess attainment of steady state. Statistics has been presented on geometric least square means.
Time frame: Day 1 (24 hours), Day 12 (Pre-dose ), Day 13 (Pre-dose ), Day 14 (Pre-dose), Day 14 (24 hours)
AUC (0-infinity) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A
Blood samples for the analysis of AUC (0-infinity) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. AUC(0-infinity) following single doses was used for assessment of dose proportionality.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
AUC (0-t) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A
Blood samples for the analysis of AUC (0-t) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. AUC(0-t) following single doses was used for assessment of dose proportionality.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Cmax as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A
Blood samples for the analysis of Cmax were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. Cmax following single doses was used for assessment of dose proportionality.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
AUC (0-tau) as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B
Blood samples for the assessment of AUC (0-tau) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. AUC (0-tau) following repeat doses was used for assessment of dose proportionality.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
Cmax as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B
Blood samples for the assessment of Cmax were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. Cmax following repeat doses was used for assessment of dose proportionality.
Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
This was a double blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of single and repeat doses of GSK3036656 in healthy adult participants. The study was conducted at 1 center in United Kingdom from 02-April-2017 to 04-August-2017. Part A was a crossover design, Part B was a parallel group design..
| Milestone | PartA - Placebo/15 mg/25 mg/5 mg (Fed) | PartA - Placebo/15 mg/25 mg/Placebo | PartA - 5 mg/Placebo/25 mg/5 mg (Fed) | PartA - 5 mg/Placebo/25 mg/Placebo | PartA - 5 mg/15 mg/Placebo/5 mg (Fed) | PartA - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Completed | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PartA - Placebo/15 mg/25 mg/5 mg (Fed) | PartA - Placebo/15 mg/25 mg/Placebo | PartA - 5 mg/Placebo/25 mg/5 mg (Fed) | PartA - 5 mg/Placebo/25 mg/Placebo | PartA - 5 mg/15 mg/Placebo/5 mg (Fed) | PartA - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Completed | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PartA - Placebo/15 mg/25 mg/5 mg (Fed) | PartA - Placebo/15 mg/25 mg/Placebo | PartA - 5 mg/Placebo/25 mg/5 mg (Fed) | PartA - 5 mg/Placebo/25 mg/Placebo | PartA - 5 mg/15 mg/Placebo/5 mg (Fed) | PartA - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Personal reasons | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PartA - Placebo/15 mg/25 mg/5 mg (Fed) | PartA - Placebo/15 mg/25 mg/Placebo | PartA - 5 mg/Placebo/25 mg/5 mg (Fed) | PartA - 5 mg/Placebo/25 mg/Placebo | PartA - 5 mg/15 mg/Placebo/5 mg (Fed) | PartA - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PartA - Placebo/15 mg/25 mg/5 mg (Fed) | PartA - Placebo/15 mg/25 mg/Placebo | PartA - 5 mg/Placebo/25 mg/5 mg (Fed) | PartA - 5 mg/Placebo/25 mg/Placebo | PartA - 5 mg/15 mg/Placebo/5 mg (Fed) | PartA - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Completed | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reaction to ecg tabs causing a rash | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PartA - Placebo/15 mg/25 mg/5 mg (Fed) | PartA - Placebo/15 mg/25 mg/Placebo | PartA - 5 mg/Placebo/25 mg/5 mg (Fed) | PartA - 5 mg/Placebo/25 mg/Placebo | PartA - 5 mg/15 mg/Placebo/5 mg (Fed) | PartA - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Completed | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PartA - Placebo/15 mg/25 mg/5 mg (Fed) | PartA - Placebo/15 mg/25 mg/Placebo | PartA - 5 mg/Placebo/25 mg/5 mg (Fed) | PartA - 5 mg/Placebo/25 mg/Placebo | PartA - 5 mg/15 mg/Placebo/5 mg (Fed) | PartA - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Completed | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PartA - Placebo/15 mg/25 mg/5 mg (Fed) | PartA - Placebo/15 mg/25 mg/Placebo | PartA - 5 mg/Placebo/25 mg/5 mg (Fed) | PartA - 5 mg/Placebo/25 mg/Placebo | PartA - 5 mg/15 mg/Placebo/5 mg (Fed) | PartA - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above. Safety Population comprised of all randomized participants who received at least one dose of study medication.
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| nSAE | 1 | 1 | 1 | 3 | 1 |
| SAE | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above.
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| nSAE | 0 | 2 | 1 |
| SAE | 0 | 0 | 0 |
12-lead ECGs were collected during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) intervals. At each time point at which triplicate ECGs were required, three individual ECG tracings were obtained as closely as possible in succession, but no more than 2 to 5 minutes apart. ECG findings were categorized as normal, abnormal not clinically significant (A-NCS) and abnormal clinically significant (A-CS). Only A-NCS and A-CS worst case post-Baseline values have been presented. Only those participants with data available at the indicated time point were analyzed.
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| A-NCS | 2 | 1 | 0 | 0 | 0 |
| A-CS | 0 | 0 | 0 | 0 | 0 |
12-lead ECGs were collected during the study using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT interval and QTcF intervals. At each time point at which triplicate ECGs were required, three individual ECG tracings were obtained as closely as possible in succession, but no more than 2 to 5 minutes apart. ECG findings were categorized as normal, A-NCS and A-CS. Only A-NCS and A-CS worst case post-Baseline values have been presented.
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| A-NCS | 1 | 3 | 3 |
| A-CS | 0 | 0 | 0 |
Continuous cardiac telemetry was performed from approximately 1 hour pre-dose to 24 hours post dosing . Number of participants who had abnormal findings upon cardiac telemetry assessment have been presented.
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Abnormal Cardiac Telemetry Findings for Part A | 0 | 0 | 0 | 0 | 0 |
Continuous cardiac telemetry was performed from approximately 1 hour pre-dose to 24 hours post dosing . Number of participants who had abnormal findings upon cardiac telemetry assessment have been presented.
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| Number of Participants With Abnormal Cardiac Telemetry Findings for Part B | 0 | 0 | 0 |
SBP and DBP were assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for SBP was less than 85 mmHg (lower) and greater than 160 mmHg (upper) while that for DBP was less than 45 mmHg (lower) and greater than 100 mmHg (upper).
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| SBP | 0 | 0 | 0 | 0 | 0 |
| DBP | 0 | 0 | 0 | 0 | 0 |
SBP and DBP were assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for SBP was less than 85 mmHg (lower) and greater than 160 mmHg (upper) while that for DBP was less than 45 mmHg (lower) and greater than 100 mmHg (upper).
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| SBP | 0 | 0 | 0 |
| DBP | 0 | 0 | 1 |
Heart rate was assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for heart was less than 40 bpm (lower) and greater than 110 bpm (upper).
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part A | 0 | 0 | 0 | 0 | 0 |
Heart rate was assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for heart was less than 40 bpm (lower) and greater than 110 bpm (upper).
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part B | 0 | 0 | 0 |
Number of participants with temperature data of PCI have been presented.
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Vital Sign Parameter Temperature of PCI for Part A | 0 | 0 | 0 | 0 | 0 |
Number of participants with temperature data of PCI have been presented.
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| Number of Participants With Vital Sign Parameter Temperature of PCI for Part B | 0 | 0 | 0 |
Blood samples were collected for the assessment of clinical chemistry parameters namely blood urea nitrogen (BUN), creatinine, glucose, cholesterol, potassium, sodium, calcium, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, triglycerides, total and direct bilirubin, total protein, albumin and troponin. Only categories with PCI values have been presented, therefore only AST is presented.
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Clinical Chemistry Parameters of PCI for Part A | 0 | 0 | 0 | 0 | 1 |
Blood samples were collected for the assessment of clinical chemistry parameters namely BUN, creatinine, glucose, cholesterol, potassium, sodium, calcium, AST, ALT, alkaline phosphatase, triglycerides, total and direct bilirubin, total protein, albumin and troponin. Only categories with PCI values have been presented.
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| ALT | 0 | 1 | 0 |
| AST | 0 | 1 | 0 |
Blood samples were collected for the assessment of hematology parameters platelet count, red blood cell count, hemoglobin, hematocrit, reticulocytes, mean corpuscle volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, basophils and eosinophils. Only categories with PCI values have been presented.
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Hematology Parameters of PCI for Part A | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for the assessment of hematology parameters platelet count, red blood cell count, hemoglobin, hematocrit, reticulocytes, mean corpuscle volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, basophils and eosinophils. Only categories with PCI values have been presented.
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| Leukocytes | 0 | 1 | 0 |
| Neutrophils | 0 | 1 | 1 |
Urinalysis included dipstick urine test which was used to screen for glucose, ketones, occult blood and protein up to 72 hours post dose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, ketones, occult blood and protein can be read as negative, trace, trace-intact, trace-lysed,1+ and 2+ indicating proportional concentrations in the urine sample. Only categories with non-negative values have been presented. Only those participants with data available the indicated time points were analyzed.
| Participants | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| Day -1, Ketone, Trace | 1 | 0 | 1 | 0 | 0 |
| Day -1, Occult blood, 1+ | 0 | 0 | 0 | 0 | 1 |
| Day -1, Occult blood, 2+ | 0 | 0 | 1 | 0 | 0 |
| Day -1, Occult blood, trace-intact | 1 | 0 | 0 | 0 | 0 |
| Day -1, Occult blood, trace-lysed | 1 | 0 | 0 | 0 | 0 |
| Day -1, Protein, Trace | 1 | 0 | 2 | 0 | 1 |
| 24 hours, Ketones, 2+ | 1 | 0 | 0 | 0 | 0 |
| 24 hours, Occult blood, 2+ | 0 | 0 | 1 | 0 | 0 |
| 24 hours, Occult blood, trace-intact | 1 | 0 | 0 | 0 | 0 |
| 24 hours, Occult blood, trace-lysed | 1 | 0 | 0 | 0 | 0 |
| 72 hours, Ketone, Trace | 0 | 0 | 1 | 0 | 0 |
| 72 hours, Occult blood, 1+ | 1 | 0 | 1 | 0 | 0 |
| 72 hours, Occult blood, trace-intact | 0 | 0 | 0 | 0 | 1 |
| 72 hours, Occult blood, trace-lysed | 0 | 0 | 0 | 1 | 0 |
| 72 hours, Protein, Trace | 2 | 0 | 0 | 0 | 0 |
Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 72 hours in Part A. Only those participants with data available at the indicated time points were analyzed.
| pH | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|---|
| pH at Day -1 | 6.08 ± 0.469 | 6.00 ± 0.548 | 5.50 ± 0.548 | 5.92 ± 0.492 | 6.70 ± 1.483 |
| pH at 24 hours | 6.04 ± 0.498 | 6.50 ± 0.447 | 5.83 ± 0.258 | 6.08 ± 0.204 | 6.80 ± 1.095 |
| pH at 72 hours | 6.46 ± 0.753 | 6.00 ± 1.095 | 5.92 ± 0.492 | 6.42 ± 0.665 | 7.30 ± 0.671 |
Urinalysis included dipstick urine test which was used to screen for glucose, ketones, occult blood and protein up to 14 days post dose The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, ketones, occult blood and protein can be read as negative, trace, trace-intact, trace-lysed, 1+ and 2+ indicating proportional concentrations in the urine sample. Only categories with non-negative values have been presented. Only those participants available at the specified time points were analyzed represented by n=x in the category titles. Period 1 = Cohort 1 in Part B, Period 2 = Cohort 2 in Part B.
| Participants | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| Day -1, Ketones, Trace,n=2,7,0 | 0 | 1 | — |
| Day -1, Occult blood,Trace-intact,n=2,7,0 | 1 | 0 | — |
| Day 14, Ketones, Trace,n=2,7,0 | 0 | 1 | — |
| Day 14, protein, 1+,n=2,7,0 | 0 | 1 | — |
| Day -1,Occult blood,Trace-intact,n=2,0,8 | 1 | — | 2 |
| Day 6,Occult blood,Trace-intact,n=2,0,8 | 0 | — | 1 |
| Day 6,Occult blood,Trace-lysed,n=2,0,8 | 0 | — | 2 |
| Day 10, Ketones, Trace,n=2,0,8 | 0 | — | 1 |
| Day 14, Protein, 2+,n=2,0,8 | 0 | — | 1 |
| Follow-up (week 8), Ketones, n=4,7,8 | 0 | 0 | 1 |
| Follow up (week 8), Occult blood, n=4,7,8 | 1 | 0 | 1 |
| Follow-up(week 8),Occult blood,Trace-lysed,n=4,7,8 | 0 | 0 | 2 |
Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 8 weeks in Part B. Only those participants available at the specified time points were analyzed represented by n=x in the category titles. Period 1 = Cohort 1 in Part B, Period 2 = Cohort 2 in Part B.
| pH | Part B-Matching Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|---|
| pH, Period 1, Day -1, n=2, 7, 0 | 6.25 ± 0.354 | 6.71 ± 0.906 | — |
| pH, Period 1, Day 4, n= 2, 7, 0 | 6.25 ± 0.354 | 5.79 ± 0.393 | — |
| pH, Period 1, Day 6, n=2, 7, 0 | 6.25 ± 0.354 | 6.43 ± 0.535 | — |
| pH, Period 1, Day 10, n=2, 7, 0 | 6.25 ± 0.354 | 6.14 ± 0.244 | — |
| pH, Period 1, Day 14, n=2, 7, 0 | 6.75 ± 0.354 | 7.00 ± 0.957 | — |
| pH, Period 2, Day -1, n=2, 0, 8 | 6.50 ± 0.707 | — | 6.81 ± 0.594 |
| pH, Period 2, Day 4, n=2, 0, 8 | 5.50 ± 0.707 | — | 6.25 ± 0.378 |
| pH, Period 2, Day 6, n=2, 0, 8 | 6.50 ± 0.000 | — | 6.69 ± 0.458 |
| pH, Period 2, Day 10, n=2, 0, 8 | 6.00 ± 0.000 | — | 6.38 ± 0.354 |
| pH, Period 2, Day 14, n=2, 0, 8 | 6.00 ± 0.000 | — | 6.38 ± 0.582 |
| pH, Follow-up (week 8), n=4, 7, 8 | 6.63 ± 0.750 | 6.29 ± 0.488 | 6.88 ± 0.744 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 Ethylenediaminetetraacetic acid (EDTA) tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. PK population comprised of participants in the Safety population who administered at least one dose of active treatment and had at least one evaluable PK sample.
| hour*nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part A | 771.0468 ± 26.0 | 3252.9152 ± 24.1 | 5686.4151 ± 11.4 | 782.7766 ± 18.1 |
Cmax will be derived from the PK samples collected at the indicated time points Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.
| hour*nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| AUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part A | 1404.5416 ± 29.9 | 3796.1488 ± 19.8 | 6557.7764 ± 13.8 | 1450.7468 ± 9.4 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.
| nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| Maximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part A | 49.06 ± 30.5 | 177.61 ± 23.1 | 207.38 ± 18.5 | 47.37 ± 23.5 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.
| hours | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part A | 1.250 (0.50 to 1.50) | 1.000 (0.50 to 2.00) | 0.875 (0.75 to 2.00) | 2.000 (1.00 to 4.00) |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.
| hours | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part A | 38.3230 (25.632 to 70.970) | 28.4128 (24.462 to 32.497) | 47.9680 (35.996 to 67.360) | 32.4248 (30.449 to 46.455) |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1. The actual date and time of each blood sample collection was recorded. Results presented are for Day 1.
| hour*nanograms/milliliter | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| AUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part B | 485.5625 ± 12.3 | 1891.0416 ± 9.9 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14The actual date and time of each blood sample collection was recorded. Results presented are for Day 14.
| hour*nanograms/milliliter | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| AUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part B | 1392.2221 ± 12.5 | 4461.2565 ± 23.7 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. The actual date and time of each blood sample collection was recorded.
| nanograms/milliliter | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| Day 1 | 48.40 ± 33.6 | 178.79 ± 32.8 |
| Day 14 | 97.04 ± 19.8 | 309.55 ± 20.2 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. The actual date and time of each blood sample collection was recorded.
| hours | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| Day 1 | 1.0000 (0.500 to 3.000) | 0.7500 (0.500 to 1.500) |
| Day 14 | 0.7500 (0.500 to 1.500) | 0.7500 (0.500 to 1.500) |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14. The actual date and time of each blood sample collection was recorded. Results presented are for Day 14.
| hours | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| t1/2 of GSK3036656 Following Repeated Dose Administration for Part B | 40.1802 (30.843 to 66.636) | 34.5109 (24.758 to 54.625) |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
| hours*nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| AUC (0-t) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A | 771.0468 ± 26.0 | 3252.9152 ± 24.1 | 5686.4151 ± 11.4 | 782.7766 ± 18.1 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
| hours*nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| AUC (0-infinity) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A | 1404.5416 ± 29.9 | 3796.1488 ± 19.8 | 6557.7764 ± 13.8 | 1450.7468 ± 9.4 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
| nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| Cmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A | 49.06 ± 30.5 | 177.61 ± 23.1 | 207.38 ± 18.5 | 35.54 ± 23.5 |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
| hours | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| t1/2 of GSK3036656 Following Single Dose Administration in Fed Condition in Part A | 38.3230 (25.632 to 70.970) | 28.4128 (24.462 to 32.497) | 47.9680 (35.996 to 67.360) | 32.4248 (30.449 to 46.455) |
Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.
| hours | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| Tmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A | 1.250 (0.50 to 1.50) | 1.000 (0.50 to 2.00) | 0.875 (0.75 to 2.00) | 2.000 (1.00 to 4.00) |
AUC Ro was calculated as Day 14 AUC(0-tau)/Day 1 AUC(0-t), where t and tau= 24 hours.
| Ratio of AUC | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| Observed Accumulation Ratio Based on AUC (AUC [Ro]) of GSK3036656 in Part B | 2.8672 ± 9.1 | 2.3592 ± 21.6 |
Rcmax was calculated as Day 14 Cmax/Day 1 Cmax. Statistics has been presented on geometric least square means.
| Ratio of Cmax | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| Observed Accumulation Ratio Based on Cmax (RCmax) of GSK3036656 in Part B | 2.0052 ± 24.3 | 1.7313 ± 26.7 |
Rss was calculated as Day 14 AUC (0-tau)/Day 1 AUC (0-inf). It was not possible to calculate AUC(0-inf) on Day 1 for the repeat dosing period, therefore it was not possible to calculate the (Rss).Na indicates data was not available.
| Ratio of AUC | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| Steady State Ratio (Rss) of GSK3036656 in Part B | NA ± NA | NA ± NA |
Blood samples for the analysis of Ctau were collected at Day 1 (24 hours), Day 12 (Pre-dose ), Day 13 (Pre-dose ), Day 14 (Pre-dose), Day 14 (24 hours). Ctau samples collected were used to assess attainment of steady state. Statistics has been presented on geometric least square means.
| nanograms/milliliter | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| Day 1, 24 hours | 14.32 ± 10.8 | 57.69 ± 10.5 |
| Day 12, Pre-dose | 38.31 ± 20.8 | 139.14 ± 21.6 |
| Day 13, Pre-dose | 41.78 ± 14.5 | 131.77 ± 28.8 |
| Day 14, Pre-dose | 43.66 ± 15.1 | 139.54 ± 32.5 |
| Day 14, 24 hours | 44.34 ± 14.8 | 139.25 ± 28.2 |
Blood samples for the analysis of AUC (0-infinity) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. AUC(0-infinity) following single doses was used for assessment of dose proportionality.
| hours*nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| AUC (0-infinity) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A | 1404.5416 ± 29.9 | 3796.1488 ± 19.8 | 6557.7764 ± 13.8 | 1450.7468 ± 9.4 |
Blood samples for the analysis of AUC (0-t) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. AUC(0-t) following single doses was used for assessment of dose proportionality.
| hours*nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| AUC (0-t) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A | 771.0468 ± 26.0 | 3252.9152 ± 24.1 | 5686.4151 ± 11.4 | 782.7766 ± 18.1 |
Blood samples for the analysis of Cmax were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. Cmax following single doses was used for assessment of dose proportionality.
| hours*nanograms/milliliter | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) |
|---|---|---|---|---|
| Cmax as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A | 49.06 ± 30.5 | 177.61 ± 23.1 | 207.38 ± 18.5 | 47.37 ± 23.5 |
Blood samples for the assessment of AUC (0-tau) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. AUC (0-tau) following repeat doses was used for assessment of dose proportionality.
| hours*nanograms/milliliter | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| AUC (0-tau) as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B | 1392.2221 ± 12.5 | 4461.2565 ± 23.7 |
Blood samples for the assessment of Cmax were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. Cmax following repeat doses was used for assessment of dose proportionality.
| nanograms/milliliter | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg |
|---|---|---|
| Day 1 | 48.40 ± 33.6 | 178.79 ± 32.8 |
| Day 14 | 97.04 ± 19.8 | 309.55 ± 20.2 |
Collected over nSAEs and SAEs were collected from Day -1 until 12 weeks in Part A and until 8 weeks in Part B.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A-Matching Placebo | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Part A-GSK3036656 5 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A-GSK3036656 15 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A-GSK3036656 25 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A-GSK3036656 5 mg (Fed) | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Part B-Matching Placebo | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Part B-GSK3036656 5 mg | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Part B-GSK3036656 15 mg | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Part A-Matching Placebo | Part A-GSK3036656 5 mg | Part A-GSK3036656 15 mg | Part A-GSK3036656 25 mg | Part A-GSK3036656 5 mg (Fed) | Part B-Matching Placebo | Part B-GSK3036656 5 mg | Part B-GSK3036656 15 mg |
|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/9 | 0/6 | 0/6 | 2/6 | 0/5 | 0/4 | 0/7 | 0/8 |
| HeadacheNervous system disorders | 0/9 | 0/6 | 1/6 | 1/6 | 0/5 | 0/4 | 2/7 | 0/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/9 | 0/6 | 0/6 | 0/6 | 1/5 | 0/4 | 0/7 | 0/8 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/9 | 1/6 | 0/6 | 0/6 | 0/5 | 0/4 | 0/7 | 0/8 |
| Medical device site dermatitisGeneral disorders | 0/9 | 0/6 | 0/6 | 1/6 | 0/5 | 0/4 | 0/7 | 0/8 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/9 | 0/6 | 0/6 | 1/6 | 0/5 | 0/4 | 0/7 | 0/8 |
| DizzinessNervous system disorders | 0/9 | 0/6 | 0/6 | 0/6 | 0/5 | 0/4 | 1/7 | 0/8 |
| Medical device site reactionGeneral disorders | 0/9 | 0/6 | 0/6 | 0/6 | 0/5 | 0/4 | 1/7 | 0/8 |
| Infectious mononucleosisInfections and infestations | 0/9 | 0/6 | 0/6 | 0/6 | 0/5 | 0/4 | 1/7 | 0/8 |
| Liver function test increasedInvestigations | 0/9 | 0/6 | 0/6 | 0/6 | 0/5 | 0/4 | 1/7 | 0/8 |
9 participants were randomized at the beginning of Part A. During Part A, 2 of the 3 participants who withdrew were replaced, hence 11 randomized.
| Age, Continuous(Years) | Part A - Placebo/15 mg/25 mg/5 mg (Fed) | Part A - Placebo/15 mg/25 mg/Placebo | Part A - 5 mg/Placebo/25 mg/5 mg (Fed) | Part A - 5 mg/Placebo/25 mg/Placebo | Part A - 5 mg/15 mg/Placebo/5 mg (Fed) | Part A - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.7 ± 5.03 | 25 ± NA | 26.3 ± 2.52 | 28.0 ± NA | 34.0 ± 1.41 | 50.0 ± NA | 30.3 ± 9.43 | 31.9 ± 6.26 | 35.1 ± 7.88 | 32.5 ± 7.39 |
| Sex: Female, Male(Participants) | Part A - Placebo/15 mg/25 mg/5 mg (Fed) | Part A - Placebo/15 mg/25 mg/Placebo | Part A - 5 mg/Placebo/25 mg/5 mg (Fed) | Part A - 5 mg/Placebo/25 mg/Placebo | Part A - 5 mg/15 mg/Placebo/5 mg (Fed) | Part A - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Male | 3 | 1 | 3 | 1 | 2 | 0 | 4 | 7 | 8 | 29 |
| Race/Ethnicity, Customized(Participants) | Part A - Placebo/15 mg/25 mg/5 mg (Fed) | Part A - Placebo/15 mg/25 mg/Placebo | Part A - 5 mg/Placebo/25 mg/5 mg (Fed) | Part A - 5 mg/Placebo/25 mg/Placebo | Part A - 5 mg/15 mg/Placebo/5 mg (Fed) | Part A - 5 mg/15 mg/Placebo/Placebo | Part B-Placebo | Part B-Repeat GSK3036656 5 mg | Part B-Repeat GSK3036656 15 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian/Alaskan Native | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian-South Asian Heritage | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Black/ African American | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| White-White/Caucasian/European Heritage | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 5 | 8 | 23 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in Aug 2017, 4 months.
Results were first posted in Apr 2019, 1 year 8 months after primary completion.
Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK656